智通财经APP获悉,周四,次新股Turn Therapeutics(TTRX.US)股价上涨,截至发稿,该股涨超144%,报16.95美元。Turn Therapeutics致力于开发下一代皮肤病、伤口和抗感染疗法。该公司拥有一种专有的递送平台技术 “PermaFusion®”,该技术旨在让水溶性的活性成分在无需乳化剂的情况下,以油性载体渗透进入皮肤、指甲或黏膜,从而增强可用性和减少刺激性。
智通财经APP获悉,周四,次新股Turn Therapeutics(TTRX.US)股价上涨,截至发稿,该股涨超144%,报16.95美元。Turn Therapeutics致力于开发下一代皮肤病、伤口和抗感染疗法。该公司拥有一种专有的递送平台技术 “PermaFusion®”,该技术旨在让水溶性的活性成分在无需乳化剂的情况下,以油性载体渗透进入皮肤、指甲或黏膜,从而增强可用性和减少刺激性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.